Home › Non-Hodgkin Lymphoma › NCT00131014
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed. * Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study. * Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research. * Age \> 18 years Exclusion Criteria: * Subjects without a family history of lymphoma
About the study
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.
Sponsor: Dana-Farber Cancer Institute · Participants: 1,500 · Started: Aug 9, 2004
Contact the study team
- Celeste Carey, MS · Phone: 857-215-1646
- Jennifer Brown, MD PhD · Phone: 617-632-4564
Official record on ClinicalTrials.gov — NCT00131014
Locations in the U.S.
| Massachusetts | Dana-Farber Cancer Institute, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.